keryx biopharmaceuticals
(KERX:NASDAQ CM)
keryx biopharmaceuticals (KERX) Snapshot
|
Open
$8.05
|
Previous Close
$8.00
|
|
|
Day High
$8.15
|
Day Low
$7.92
|
|
|
52 Week High
01/31/13 - $9.98
|
52 Week Low
05/21/12 - $1.55
|
|
|
Market Cap
657.0M
|
Average Volume 10 Days
2.6M
|
|
|
EPS TTM
$-0.26
|
Shares Outstanding
81.7M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
keryx biopharmaceuticals (KERX) Related Businessweek News
No Related Businessweek News Foundkeryx biopharmaceuticals (KERX) Details
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Zerenex is also in Phase II development for the management of phosphorus and iron deficiency in anemic patients with stages three to five non-dialysis dependent chronic kidney diseases. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
keryx biopharmaceuticals (KERX) Top Compensated Officers
keryx biopharmaceuticals (KERX) Key Developments
Keryx Biopharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported license revenue of $7,000,000. Operating loss was $2.158 million against $9.176 million a year ago. Net loss was $2.055 million or $0.03 per diluted share against $9.114 million or $0.13 per diluted share a year ago.
Keryx Biopharmaceuticals Inc., Q1 2013 Earnings Call, May 08, 2013
Keryx Biopharmaceuticals Inc. will held annual general meeting on June 18, 2013 to approve an amendment to Certificate of Incorporation to increase authorized share capital by 35,000,000 shares.
| Recently Viewed | |||
| KERX:US | $8.04 USD | +0.04 |  |
| Company | Last | Change |
| Cell Therapeutics Inc | $1.16 USD | +0.01 |
| Curis Inc | $4.12 USD | +0.11 |
| Exact Sciences Corp | $10.56 USD | -0.26 |
| Immunomedics Inc | $3.14 USD | +0.03 |
| Navidea Biopharmaceuticals Inc | $2.39 USD | +0.04 |
| View Industry Companies | ||
Industry Analysis
KERX
Industry Average
| Valuation | KERX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 89.1x |
|
| Price/Book | 7.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 80.9x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
